Tissue Repair Ltd (ASX: TRP) - Share Price
- Current share price for TRP : $0.110
Tissue Repair (TRP), an ASX-listed company, is a clinical-stage biopharmaceutical company engaged in developing wound-healing products targeting applications in chronic wound and aesthetic procedure aftercare markets, with potential for development of related technologies.
TRP General Information +
| ASX Code | TRP |
| Website | http://www.tissuerepair.com.au |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 6 |
| TRP Share Price | $0.110 |
| Day High | $0.000 |
| Day Low | $0.000 |
| Last Close | $0.110 |
| TRP Share Price Movement | - ( No change ) |
Prices as at 16:40, 17 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Tissue Repair Ltd (TRP) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Final | 2.75¢ | 100% | 23 Aug 1989 | 16 Oct 1989 | - | - | - |
| Interim | 2.45¢ | 100% | 22 May 1989 | 26 Jun 1989 | - | - | - |
| Final | 4¢ | 100% | 26 Sep 1988 | 14 Oct 1988 | - | - | - |
See all dividends from Tissue Repair Ltd (TRP) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Tissue Repair Ltd (TRP) price-sensitive announcements
TRP - Quarterly Activities/Appendix 4C Cash Flow Report
Tissue Repair Limited (ASX:TRP) is advancing its Phase 3 clinical trials for the TR987® dr
Tissue Repair Ltd (TRP)
30 Apr 2026 | 2:28 PM
30 Apr 2026 | 2:28 PM
TRP - Appendix 4D and Half Year Report to 31 December 2025
Tissue Repair Ltd's half-year report for the period ending 31 December 2025 indicates a co
Tissue Repair Ltd (TRP)
27 Feb 2026 | 1:53 PM
27 Feb 2026 | 1:53 PM
TRP - Quarterly Activities/Appendix 4C Cash Flow Report
Tissue Repair Limited (ASX: TRP) provided a quarterly update for the period ending 31 Dece
Tissue Repair Ltd (TRP)
30 Jan 2026 | 1:22 PM
30 Jan 2026 | 1:22 PM
TRP - Response to ASX Price Query
Tissue Repair Limited (TRP) responded to a query from the Australian Securities Exchange (
Tissue Repair Ltd (TRP)
10 Dec 2025 | 2:35 PM
10 Dec 2025 | 2:35 PM
Tissue Repair Ltd (TRP) Recent ASX Announcements
TRP Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$4.24 | -$7.00 | 2.50% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$4.14 | -$6.80 | -0.90% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$4.17 | -$6.90 | -49.80% | 0.00 | 0.00 | 0.00% | 0.0% |
TRP Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| CSL Limited (CSL) | $58,403M | 0.1108 | -0.1189 | 0.0168 | 13.0768 | 14.8421 | 14.5973 | 3.66% | 2.99% | 3.11% |
| Clinuvel Pharmaceuticals Limited (CUV) | $510M | 0.0287 | 0.0000 | 0.0000 | 14.0808 | 0.0000 | 0.0000 | 0.49% | 0.00% | 0.00% |
| Mesoblast Limited (MSB) | $3,592M | 0.0301 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $5,304M | -1.3893 | 0.0000 | -0.1300 | 0.0000 | 285.8974 | 328.6316 | 0.00% | 0.00% | 0.00% |
| Tissue Repair Ltd (TRP) | $7M | 0.0249 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
TRP Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 0.48 | 0.00 |
| Market | 0.31 | 12.90 | 1.13 | 0.58 |
| Sector | 0.46 | 28.10 | 2.54 | 1.89 |
TRP Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Tony Charara | Co-Founder, Executive Director | 17 May 2012 |
| Mr Peter Scutt | Executive Director | 20 Apr 2026 |
| Mr Alistair Gregory McKeough | Non-Executive Chairman, Non-Executive Director | 25 Oct 2024 |
| Mr Patryk Kania | Non-Executive Director | 25 Oct 2024 |
Tissue Repair Ltd (TRP) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 26 Nov 2025 | MCKEOUGH, Alistair | Buy | Direct Shares | 30,000 | $0.293 | $8,775.000 |
| 2 Jun 2023 | LOWENSTEIN, Jack | Buy | Indirect Shares | 40,000 | $0.280 | $11,200.000 |
| 30 May 2023 | LOWENSTEIN, Jack | Buy | Direct Shares | 35,000 | $0.280 | $9,800.000 |
See all changes in directors' interest & trades for Tissue Repair Ltd (TRP) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
TRP Management
| Name | Position |
|---|---|
| Sushma Kejriwal | Company Secretary |
TRP Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Tissue Repair Ltd (TRP). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 5,955,980 (9.85%) | Selene Holdings Ltd |
| 4,822,260 (7.98%) | Spark Capital Pty Ltd And Tony Charara |
| 3,990,000 (6.60%) | Hishenk Pty Ltd |
| 3,031,720 (5.01%) | Creight Investments Pty Ltd, Peter Scutt and Nadia Jacob |
TRP Calendar of Events
| Date | Event |
|---|---|
| 26 February 2027 | Report (Interim) |
| 28 August 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
